Improving prostate cancer treatment with enzalutamide
Official title: Developing therapies to improve enzalutamide in CRPC
Funded at Oregon Health & Science University · NIH-11056069 · Data updated 2026-11-12
This study is looking for ways to make enzalutamide, a treatment for metastatic prostate cancer, work better by understanding how certain proteins help cancer cells survive, so we can find new ways to help patients get better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project start | December 1, 2022 |
| Project end | November 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $416,508 |
| NIH project number | 5R01CA270271-03 |
| Project ID | NIH-11056069 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with castration-resistant prostate cancer who have experienced limited success with current enzalutamide treatments.
✕Less likely to help
Patients with early-stage prostate cancer or those who have not been treated with enzalutamide may not benefit from this research.
What this research studies
This research aims to enhance the effectiveness of enzalutamide, a treatment for metastatic prostate cancer that has shown promise but often leads to resistance in patients. By investigating the role of glutamic pyruvate transaminases (GPT) in cancer cell survival, the study seeks to identify new therapeutic strategies that can improve patient outcomes. The researchers will utilize advanced techniques, including CRISPR/Cas9 screening, to explore how GPT contributes to resistance against enzalutamide and to test potential inhibitors that could enhance treatment efficacy.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for men with castration-resistant prostate cancer, potentially improving survival rates.
How similar studies have gone: Previous research has shown promise in targeting metabolic pathways in cancer treatment, suggesting that this approach could yield significant advancements.
Where this research is happening
-
Oregon Health & Science University
Portland, United States Active
Researchers
- Principal investigator: Qian, Zheng David — Oregon Health & Science University
- Study coordinator: Qian, Zheng David
Related research
Other NIH-funded projects on the same topics.
-
Understanding how a protein affects nerve cell movement in Alzheimer's disease
This study is looking at how a protein called APP affects the growth and movement of nerve cells, which is important for understanding Alzheimer's disease, and it aims to find out how problems with this protein might lead to nerve cell damage.
-
Understanding how the bone marrow environment drives AML resistance
A large NIH-funded project at Oregon Health & Science University is studying how the body’s own cell surroundings help acute myeloid leukemia become resistant to treatment, with potential paths to better therapies for patients.
-
Improving Safety at Work with a Low-Resource mHealth Program in Malaysia (and beyond)
A low-cost mobile health program to improve safety culture in Malaysian workplaces, with plans to adapt the approach for U.S. workers in high-risk industries.
-
Oregon Healthy Workplace Initiative for Better Health
A multi-site effort aims to improve the health and safety of workers by coordinating research, tools, and interventions across workplaces.
-
Understanding how AML cells become resistant to therapy over time
This project looks at why acute myeloid leukemia stops responding to treatment and how to design better drug combinations to prevent relapse.
-
Mechanisms and Countermeasures for Ultra-Potent Synthetic Opioid Overdose
A small, focused NIH grant aims to understand why ultra-potent synthetic opioids cause severe overdose and to explore potential countermeasures to keep people safe.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.